| Overview | EMD millipore’s MILLIPLEX® MAP Equine Cytokine Magnetic Bead Panel is a 23-plex kit to be used for the simultaneous quantification of any or all of the following analytes in serum, plasma or culture supernatant samples: Eotaxin/CCL11, FGF-2. Fractalkine/CS3CL1, G-CSF, GM-CSF, GRO, IFN, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8/CXCL8, IL-10, IL-12 (p70), IL-13, IL-17a, IL-18, IP-10, MCP-1, RANTES/CCL5 and TNFα.
MILLIPLEX® MAP offers the broadest selection of analytes across a wide range of disease states and species. Once the analytes of interest have been identified, you can rely on the quality that we build into each kit to produce results you can trust. In addition to the assay characteristics listed in the protocol, other performance criteria evaluated during the validation process include: cross-reactivity, dilution linearity, kit stability, and sample behavior (e.g. detectability and stability). Each panel and kit meets stringent manufacturing criteria to ensure batch-to-batch reproducibility.
Each MILLIPLEX® MAP panel and kit includes:
- Quality controls (QCs) provided to qualify assay performance
- Comparison of standard (calibrator) and QC lots to a reference lot to ensure lot-to-lot consistency
- Optimized serum matrix to mimic native analyte environment
- Detection antibody cocktails designed to yield consistent analyte profiles within panel
EMD millipore’s MILLIPLEX® MAP Equine Cytokine Magnetic Bead Panel is part of the most versatile system available for cytokine research. From our single to multiplex biomarker solutions, we partner with you to design, develop, analytically validate and build the most comprehensive library available for protein detection and quantitation. |
| Background Information | Inflammation and immune cell response are key to maintaining homeostasis. The more we understand the mechanisms of disease, the more we discover the role that inflammation plays in the etiology of disease. This is a true for horses as it is for humans. Both experience immunological diseases, such as infectious disease, osteoarthritis and respiratory disease, as well as neurologic, metabolic and cardiovascular disease and even cancer. However, until now the ability to measure levels of cytokines and chemokine in horses has been limited primarily to ELISAs. However, researchers will now the ability to measure multiple inflammation biomarkers simultaneously using EMD millipore’s MILLIPLEX® MAP Equine Cytokine/Chemokine Panel, based on the Luminex xMAP® technology. |
